Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers
Received 28 February 2020
Accepted for publication 16 May 2020
Published 8 June 2020 Volume 2020:12 Pages 589—594
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Vera Ehrenstein
Christian Madelaire,1 Finn Gustafsson,2,3 Lars Køber,2 Christian Torp-Pedersen,4,5 Charlotte Andersson,1,6 Søren Lund Kristensen,2 Gunnar Gislason,1,7 Morten Schou1
1Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark; 2Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 3Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 4Department of Cardiology and Clinical Research, Nordsjaellands Hospital, Hilleroed, Denmark; 5Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; 6Department of Medicine, Section of Cardiovascular Medicine, Boston Medical Center, Boston, MA, USA; 7Danish Heart Foundation, Copenhagen, Denmark
Correspondence: Christian Madelaire
Department of Cardiology, Copenhagen University Hospital Gentofte, Kildegårdsvej 28, Opgang 6, 3rd floor, Copenhagen, Denmark
Tel +45 20 92 86 45
Background: In Danish administrative registers, ejection fraction (EF) is not recorded, which is a considerable limitation for correct subclassification of patients with heart failure (HF). We hypothesized that a diagnosis of HF combined with the recorded prescription of both renin-angiotensin system (RAS) inhibitors and beta- blockers (RASi+BB) within 120 days could identify patients with HF and reduced ejection fraction (EF ≤ 40%) (HFrEF).
Methods: On two sites, we identified all patients with a first-time registration of HF as primary hospital discharge diagnosis (ICD-10: I50) between June 1, 2016, and May 31, 2018 in inpatient or outpatient settings. Patients were included if they survived the initial 120 days after discharge. Reviewing patient records, we identified patients with HFrEF, based on EF ≤ 40% and reported HF symptoms. We registered the use of RASi+BB at 120 days and calculated sensitivity, specificity and predictive values.
Results: A total of 704 consecutive patients with a primary diagnosis of HF were included, of whom 541 (77%) fulfilled the HFrEF criteria. Patients with HFrEF confirmed from patient records were younger (median age 73 compared to 79 years) and less frequently women (31% compared to 56%) compared to non-HFrEF patients. At baseline, 24 (4%) of HFrEF patients were treated with RASi+BB compared to 22 (14%) of non-HFrEF patients. At 120 days, 460 (85%) of HFrEF patients received RASi+BB as compared to 25 (15%) of non-HFrEF patients. This resulted in a positive predictive value of 95%, sensitivity of 85% and specificity of 85%.
Conclusion: In Denmark, the ICD-10 HF diagnosis combined with recorded RASi+BB treatment by 120 days after discharge has high positive predictive value and can accurately be used to identify patients with HFrEF.
Keywords: heart failure, reduced ejection fraction, register data, validation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]